The incorporation of proliferative markers like Ki‐67, PCNA, and Cyclin D1 into treatment decision‐making for pancreatic cancer is promising but comes with significant limitations that restrict their current clinical utility. This evidence concerns the gene PCNA and familial pancreatic carcinoma.